Previous Close | 363.25 |
1-Year Change | 60.28% |
6-Months Change | 32.45% |
3-Months Change | 4.21% |
Moving Avg (50d) | 362.93 |
Moving Avg (200d) | 298.7 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 17.1B |
Beta (3-Years) | 0.4 |
Revenue Growth (ttm) | 18.51% |
Net Profit Margin (ttm) | 40.69% |
Return On Assets (ttm) | 12.77% |
EPS (ttm) | 18.13 |
PE Ratio (ttm) | 20.04 |
Dividend Yield | % |
Asset Description: | United Therapeutics Corporation |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-11-21 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
365.432 | 354.246 | 346.788 | 335.601 | 316.957 | 298.312 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.